Hitachi Rail GTS UK Limited

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. The company focuses on innovation to prevent and treat disease, aiming to positively impact the health of 2.5 billion people by the end of the decade. GSK combines leading vaccines and specialty medicines to create meaningful impact for patients worldwide. With headquarters in London and a significant global footprint, GSK employs thousands of people across commercial, R&D, manufacturing, and corporate functions. The company operates in key therapeutic areas including respiratory, immunology, oncology, HIV, and infectious diseases, pushing the frontiers of science to improve health outcomes globally.

StreSERT Integrated Limited (SIL) is an African-focused management consulting firm dedicated to partnering with clients and stakeholders to create solutions that deliver significant, measurable impact. The company integrates deep capabilities in building partnerships, problem-solving, talent development, and organizational improvement to craft forward-looking solutions that change the status quo. SIL seeks to be at the vanguard of changing the African narrative, helping unlock the enormous potential of the continent's people, businesses, and governments. SIL's core capabilities span Strategy, Change Management, Business Process Outsourcing/Managed Services, People and Organization Improvement, Executive Search & Talent Management, Job Evaluation, and Reward & Compensation Design. As the exclusive partner of Kotter Training in Nigeria and West Africa, SIL offers the first-ever Kotter Change Certification programs in the region. The firm approaches every engagement with the goal of achieving a minimum 10x return on investment, guided by principles of genuine partnerships, fact-based insights, strategic answers, and transformative value. SIL serves diverse industries including Agriculture, Construction, Education, Oil & Gas, Public Sector, and SMEs, driving organizational transformation and sustainable growth.

In 1996, when Claude Bébéar, chairman of AXA, asked Dominique Senequier to create a private equity arm for the insurer, a remarkable journey began. Bébéar promised to invest one franc for every two she raised from outside investors, a challenge that ignited a fierce determination in the young company to win clients through exceptional service and outstanding investment performance. Starting with just a $100m French Buyout fund and two external clients, the company steadily expanded into new asset classes and built a powerful international network across Europe, North America, and Asia. The pivotal moment arrived in 2013, when Dominique Senequier led an employee buyout of AXA Private Equity, creating Ardian – an independent private investment firm where approximately 80% of employees became owners. This independence unlocked a new chapter of accelerated growth, transforming the company into a global diversified private markets firm managing $196bn in assets. From those humble beginnings, Ardian has evolved into a world-leading organization with over 1,000 employees across 20 offices worldwide, mastering change to create lasting value for all stakeholders.

Rhenus Group stands as one of the world's leading logistics specialists, with an annual turnover exceeding €8.2 billion and operations spanning more than 1,120 locations across Europe, Asia, the Americas, Africa, and Oceania. Employing approximately 40,000 professionals worldwide, this family-owned business has established itself as a powerhouse in the global logistics industry since its founding in Germany in 1912. Today, Rhenus manages complex supply chains through its four core business divisions: Contract Logistics, Freight Logistics, Port Logistics, and Public Transport, serving industries ranging from automotive and chemicals to healthcare and high-tech sectors. The company's comprehensive service portfolio encompasses end-to-end logistics solutions including air, sea, road, rail, and inland waterway transport, alongside advanced warehousing capabilities featuring 4 million square meters of storage space across 180 locations globally. Rhenus combines physical infrastructure with cutting-edge digital solutions, leveraging SAP systems for warehouse management and Power BI for business analytics to deliver optimized supply chain performance. As a subsidiary of the Rethmann Group, Rhenus continues to expand its global footprint while maintaining the personalized customer service approach that has defined its century-long legacy.

At JTI, we believe in the power of freedom and celebrate the differences that make each of our 46,000 team members unique. Our purpose serves as our North Star - creating fulfilling moments for consumers while building a better future. We operate as one global team across 130+ markets, embracing a growth mindset that never comes at the expense of our values. Our culture thrives on ownership, innovation, and the belief that when people are free to be themselves, the possibilities are limitless. We take pride in being a young company with a rich heritage, founded in 1999 but driven by entrepreneurial spirit. Our integrated work system embodies principles of Zero Loss, 100% Employee Ownership, and One Team, ensuring everyone contributes meaningfully. Whether in our factories, offices, or out in the field, we cultivate an environment where continuous improvement is part of our DNA and where people come first in everything we do.

Genentech pioneered the biotechnology industry and revolutionized treatment for some of the most complex health problems. For nearly 50 years, the company has pursued groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer, Genentech has consistently pushed the boundaries of what is possible in biomedical research. The company's transformational discoveries include the first personalized medicine for cancer and the first medicine for primary progressive multiple sclerosis. Today, Genentech operates as a member of the Roche Group, galvanizing the greatest minds across their business to make lasting improvements in healthcare. Their approach includes novel customer engagement strategies, state-of-the-art manufacturing facilities, and integrating AI for molecule discovery. With a $50 billion commitment to U.S. manufacturing and R&D, Genentech remains dedicated to leveling barriers to clinical trial participation, driving inclusive research, and optimizing health outcomes for all patients.